Sernova Corp.
810 - 1708 Dolphin Avenue
Kelowna
British Columbia
V1Y 9S4
Canada
Tel: 250-868-8177
Fax: 250-868-8493
Website: http://www.sernovacorp.com/
87 articles with Sernova Corp.
-
Sernova Announces Abstract on First Cohort of its Phase 1/2 Study Involving Islet Allotransplantation into Pre-vascularized Cell Pouch™ Selected for Oral Podium Presentation at American Diabetes Association 83rd Scientific Sessions 2023
3/22/2023
Sernova Corp. is pleased to announce that an abstract has been selected for an oral podium presentation at the upcoming American Diabetes Association (ADA) 83rd Scientific Sessions, to be held from June 23-26, 2023, in San Diego, CA.
-
Sernova Announces Upcoming Podium Presentation of iPSC and Cell Pouch™ Combination Treatment for Type One Diabetes at the 4th IPITA / HSCI / JDRF Summit
3/14/2023
Sernova Corp., a clinical-stage company and leader in cell therapeutics, announced that an abstract has been selected for an oral presentation at the 4th International Pancreas and Islet Transplant Association / Harvard Stem Cell Institute / Juvenile Diabetes Research Fund Summit, to be held from April 24-25, 2023 in Cambridge, Massachusetts.
-
Sernova Announces Initial Islet Transplantation in First Two Patients Enrolled in Second Cohort of its U.S. Phase 1/2 Clinical Trial for Treatment of Type 1 Diabetes
3/8/2023
Sernova Corp. announced today that the first two patients in the second cohort of its active U.S. Phase 1/2 clinical trial for the treatment of type 1 diabetes (“T1D”) and hypoglycemia unawareness received their first islet transplant into the higher capacity 10-channel Cell Pouch™.
-
Sernova to Participate in Upcoming Roth and Oppenheimer Investor ConferencesSernova provides warrant update
3/2/2023
Sernova Corp. today announced it will be participating in the upcoming 35th Annual Roth Conference being held March 12-14, 2023 and the Oppenheimer 33rd Annual Healthcare Conference, taking place March 13-15, 2023. Company management will also be participating in one-on-one investor meetings at the conferences.
-
Sernova Announces Advancements with its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy
1/30/2023
Sernova Corp. today announced advancements in its thyroid cell therapy program – one of three cell therapy development programs utilizing the Company’s proprietary Cell Pouch System™.
-
Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes
1/10/2023
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that significant progress has been achieved in its collaboration with Evotec SE (FSE: EVT; NASDAQ: EVO).
-
Sernova Corp. Announces CEO Succession Plan and Expanded Management TeamThe Company is recruiting a new CEO for its next stage of growth - Dr. Toleikis, President and CEO, to transition to Chief Technology Officer upon new appointment
12/6/2022
Sernova Corp. announced today that, as part of a planned leadership succession process, and after a successful 13-year tenure leading the Company through the development of its pioneering Cell Pouch System™ and ensuing growth, Dr. Philip Toleikis, President and Chief Executive Officer will be appointed Sernova’s Chief Technology Officer.
-
Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of its US Phase 1/2 Clinical Trial for Type 1 Diabetes
11/17/2022
Sernova Corp. announced today that the first two patients in the second cohort of its active U.S. Phase 1/2 type 1 diabetes (T1D) clinical trial have been implanted with its 10-channel Cell Pouch, which provides >50% more capacity relative to the Cell Pouches used for the first cohort.
-
Sernova to Participate in the Stifel Healthcare 2022 Conference
11/4/2022
Sernova Corp., a clinical-stage company and leader in cell therapeutics, announced it will be presenting at the upcoming Stifel Healthcare Conference being held in-person in New York, NY on November 15-16, 2022.
-
Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes
11/3/2022
Sernova Corp. is pleased to announce, in conjunction with the advancement of its ongoing Phase 1/2 clinical trial of the Sernova Cell Pouch System™ for patients with type 1 diabetes who suffer from hypoglycemia unawareness, the approval of a protocol amendment by the University of Chicago Institutional Review Board and no objections from FDA.
-
Sernova to Participate in the Roth Inaugural Healthcare Opportunities Conference
9/28/2022
Sernova Corp. today announced it will be presenting at the upcoming Roth Inaugural Healthcare Opportunities Conference being held in-person in New York, NY on October 6, 2022.
-
Sernova Announces Full Exercise of Share Purchase Warrants Expiring September 22, 2022
9/22/2022
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE / XETRA:PSH), a clinical-stage company and leader in regenerative cell therapeutics, today announced that all remaining share purchase warrants related to the 2020 private placement, expiring on September 22, 2022, have been exercised with additional proceeds of $3.5M received since the Company’s last update on September 1, 2022.
-
Sernova to Present at H.C. Wainwright Annual Global Investment Conference and LifeSci Partners HealthTech Symposium
9/8/2022
Sernova Corp. announced it will be presenting at the upcoming H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY from September 12-14, 2022, as well as the LifeSci Partners HealthTech Symposium being held September 20-21, 2022.
-
Sernova Announces the Appointment of Daniel Mahony, Ph.D. to its Board of Directors
9/7/2022
Sernova Corp., a clinical-stage company and leader in regenerative medicine cell therapeutics, announced the appointment of Daniel Mahony, Ph.D. to its Board of Directors, effective September 30th, 2022.
-
Sernova Receives Second Tranche Equity Investment from Evotec of $6.8 Million at a Price of $2.50 Per Share
9/1/2022
Sernova Corp., a clinical-stage company and leader in regenerative medicine cell therapeutics, announced that it has completed the second and final tranche of its previously announced private placement with Evotec SE of 2,709,800 common shares of the Company at a price of $2.50 per share for total proceeds of $6,774,500.
-
Sernova to Participate in the Truist Securities Cell Therapy Symposium, Symposia-cel in June
6/15/2022
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, today announced that Dr. Philip Toleikis, President & CEO of Sernova Corp, will be participating in the Truist Securities Cell Therapy Symposium, Symposia-cel being held in person at the Lotte New York Palace on Tuesday, June 28, 2022.
-
Evotec SE has inked a deal with Janssen Pharmaceutical hat showcases its end-to-end integrated drug discovery and development platform.
-
Sernova shared positive Phase I/II data from an ongoing clinical study of its implantable Cell Pouch device that showed evidence of in vivo active insulin production.
-
Sernova Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System™ at American Diabetes Association 82nd Scientific Sessions 2022
6/6/2022
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, today announced the presentation of clinical data from its Phase 1/2 clinical trial supporting the potential of its proprietary Cell Pouch System to provide a ‘functional cure’ for insulin-dependent diabetes.
-
Germany-based Evotec AG forged its third partnership in May, a deal with Spain’s Almirall S.A. to develop new therapeutics for severe diseases of the skin.